These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29752752)

  • 1. Long-term safety and efficacy of the novel β
    Yoshida M; Kakizaki H; Takahashi S; Nagai S; Kurose T
    Int J Urol; 2018 Jul; 25(7):668-675. PubMed ID: 29752752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
    Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
    Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vibegron, a Novel Potent and Selective β
    Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
    Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of novel β
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Hashimoto K; Minemura K
    Int J Urol; 2019 Mar; 26(3):369-375. PubMed ID: 30557916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).
    Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
    J Urol; 2021 May; 205(5):1421-1429. PubMed ID: 33356445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
    BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial.
    Staskin D; Owens-Grillo J; Thomas E; Rovner E; Cline K; Mujais S
    J Urol; 2024 Aug; 212(2):256-266. PubMed ID: 38708869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.
    Shi H; Chen H; Zhang Y; Cui Y
    Neurourol Urodyn; 2020 Jun; 39(5):1255-1263. PubMed ID: 32421908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
    Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
    J Urol; 2020 Aug; 204(2):316-324. PubMed ID: 32068484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder.
    Su S; Liang L; Lin J; Liu L; Chen Z; Gao Y
    Medicine (Baltimore); 2021 Feb; 100(5):e23171. PubMed ID: 33592817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vibegron (Gemtesa) for overactive bladder.
    Med Lett Drugs Ther; 2021 May; 63(1623):67-69. PubMed ID: 33976098
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
    Chen JV; Klein TM; Nesheim J; Mudd PN
    J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
    Neurourol Urodyn; 2021 Aug; 40(6):1651-1660. PubMed ID: 34139038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
    Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
    Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial Comment from Dr Chapple to Long-term safety and efficacy of the novel β
    Chapple CR
    Int J Urol; 2018 Jul; 25(7):677. PubMed ID: 29869398
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial Comment from Dr Yamanishi to Long-term safety and efficacy of the novel β
    Yamanishi T
    Int J Urol; 2018 Jul; 25(7):676. PubMed ID: 29862577
    [No Abstract]   [Full Text] [Related]  

  • 18. Vibegron: a β
    Paton DM
    Drugs Today (Barc); 2021 Aug; 57(8):507-517. PubMed ID: 34405208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive effects of intravenous and intravesical application of vibegron, a β
    Furuta A; Suzuki Y; Igarashi T; Koike Y; Kimura T; Egawa S; Yoshimura N
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2073-2080. PubMed ID: 32556396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19-01.
    Tachikawa K; Kyoda Y; Fukuta F; Kobayashi K; Masumori N
    Low Urin Tract Symptoms; 2022 Mar; 14(2):109-116. PubMed ID: 34713579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.